BACKGROUND: Prior to receiving a drug from CCR5-antagonist class in HIV therapy, a patient must undergo an HIV tropism test to confirm that his or her viral population uses the CCR5 coreceptor for cellular entry, and not an alternative coreceptor. One approach to tropism testing is to examine the sequence of the V3 region of the HIV envelope, which interacts with the coreceptor. METHODS: Viral RNA is extracted from blood plasma. The V3 region is amplified in triplicate with nested reverse transcriptase-PCR. The amplifications are then sequenced and analyzed using the software, RE_Call. Sequences are then submitted to a bioinformatic algorithm such as geno2pheno to infer viral tropism from the V3 region. Sequences are inferred to be non-R5 if their geno2pheno false positive rate falls below 5.75%. If any one of the three sequences from a sample is inferred to be non-R5, the patient is unlikely to respond to a CCR5-antagonist.
BACKGROUND: Prior to receiving a drug from CCR5-antagonist class in HIV therapy, a patient must undergo an HIV tropism test to confirm that his or her viral population uses the CCR5 coreceptor for cellular entry, and not an alternative coreceptor. One approach to tropism testing is to examine the sequence of the V3 region of the HIV envelope, which interacts with the coreceptor. METHODS: Viral RNA is extracted from blood plasma. The V3 region is amplified in triplicate with nested reverse transcriptase-PCR. The amplifications are then sequenced and analyzed using the software, RE_Call. Sequences are then submitted to a bioinformatic algorithm such as geno2pheno to infer viral tropism from the V3 region. Sequences are inferred to be non-R5 if their geno2pheno false positive rate falls below 5.75%. If any one of the three sequences from a sample is inferred to be non-R5, the patient is unlikely to respond to a CCR5-antagonist.
Authors: Luke C Swenson; Andrew Moores; Andrew J Low; Alexander Thielen; Winnie Dong; Conan Woods; Mark A Jensen; Brian Wynhoven; Dennison Chan; Christopher Glascock; P Richard Harrigan Journal: J Acquir Immune Defic Syndr Date: 2010-08 Impact factor: 3.731
Authors: T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton Journal: Nature Date: 1996-06-20 Impact factor: 49.962
Authors: David A Cooper; Jayvant Heera; James Goodrich; Margaret Tawadrous; Michael Saag; Edwin Dejesus; Nathan Clumeck; Sharon Walmsley; Naitee Ting; Eoin Coakley; Jacqueline D Reeves; Gustavo Reyes-Teran; Mike Westby; Elna Van Der Ryst; Prudence Ive; Lerato Mohapi; Horacio Mingrone; Andrzej Horban; Frances Hackman; John Sullivan; Howard Mayer Journal: J Infect Dis Date: 2010-03-15 Impact factor: 5.226
Authors: Tobias Sing; Andrew J Low; Niko Beerenwinkel; Oliver Sander; Peter K Cheung; Francisco S Domingues; Joachim Büch; Martin Däumer; Rolf Kaiser; Thomas Lengauer; P Richard Harrigan Journal: Antivir Ther Date: 2007
Authors: Roy M Gulick; Jacob Lalezari; James Goodrich; Nathan Clumeck; Edwin DeJesus; Andrzej Horban; Jeffrey Nadler; Bonaventura Clotet; Anders Karlsson; Michael Wohlfeiler; John B Montana; Mary McHale; John Sullivan; Caroline Ridgway; Steve Felstead; Michael W Dunne; Elna van der Ryst; Howard Mayer Journal: N Engl J Med Date: 2008-10-02 Impact factor: 91.245
Authors: A Gonzalez-Serna; R A McGovern; P R Harrigan; F Vidal; A F Y Poon; S Ferrando-Martinez; M A Abad; M Genebat; M Leal; E Ruiz-Mateos Journal: Antimicrob Agents Chemother Date: 2011-12-05 Impact factor: 5.191
Authors: Susan M Schader; Susan P Colby-Germinario; Peter K Quashie; Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Daniela Moisi; Thibault Mespléde; Mark A Wainberg Journal: Antimicrob Agents Chemother Date: 2012-05-21 Impact factor: 5.191
Authors: Ron M Kagan; Erik P Johnson; Martin F Siaw; Ben Van Baelen; Richard Ogden; Jamie L Platt; Rick L Pesano; Eric Lefebvre Journal: AIDS Res Hum Retroviruses Date: 2013-08-14 Impact factor: 2.205
Authors: Ron M Kagan; Erik P Johnson; Martin Siaw; Pinaki Biswas; Douglass S Chapman; Zhaohui Su; Jamie L Platt; Rick L Pesano Journal: PLoS One Date: 2012-09-27 Impact factor: 3.240
Authors: Jennifer Brown; Harold Burger; Barbara Weiser; Richard B Pollard; Xiao-Dong Li; Lynell J Clancy; Russell E Baumann; Amy A Rogers; Hasnah B Hamdan; Rick L Pesano; Ron M Kagan Journal: AIDS Res Ther Date: 2014-05-21 Impact factor: 2.250